Zyluli 1% Cream contains luliconazole 1% w/w, an imidazole antifungal agent indicated for the topical treatment of superficial dermatophytic infections such as tinea corporis, tinea cruris, and tinea pedis. Luliconazole exerts its antifungal activity by inhibiting the enzyme lanosterol 14α-demethylase, a critical component in the biosynthesis of ergosterol, an essential sterol in fungal cell membranes. This inhibition disrupts the fungal cell membrane integrity, leading to increased permeability and ultimately fungal cell death. Zyluli 1% Cream is applied once daily to the affected area and surrounding skin after cleansing and drying, typically for a duration of 2 to 4 weeks depending on the infection site and severity. The formulation is well tolerated, with minimal systemic absorption, reducing the risk of systemic adverse effects. Common local adverse reactions may include mild burning, itching, or irritation at the application site, which are generally transient. Zyluli 1% Cream should be used with caution in patients with known hypersensitivity to luliconazole or any cream excipients. It is contraindicated in mucosal fungal infections and should not be applied to open wounds or damaged skin. Proper adherence to the prescribed regimen is essential to achieve optimal therapeutic outcomes and prevent recurrence.